The Susceptibility of Trypanosomatid Pathogens to PI3/mTOR Kinase Inhibitors Affords a New Opportunity for Drug Repurposing

Phylogenomics of phosphoinositide lipid kinases: perspectives on the evolution of second messenger signaling and drug discovery

(2011) James R Brown et al.   BMC EVOLUTIONARY BIOLOGY

Trypanosome TOR complex 2 functions in cytokinesis

(2011) Antonio Barquilla et al.   CELL CYCLE

In vitro interactions between sitamaquine and amphotericin B, sodium stibogluconate, miltefosine, paromomycin and pentamidine against Leishmania donovani

(2011) K. Seifert et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

New inhibitors of the mammalian target of rapamycin signaling pathway for cancer

(2010) Sébastien Albert et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Target of Rapamycin (TOR)-like 1 Kinase Is Involved in the Control of Polyphosphate Levels and Acidocalcisome Maintenance inTrypanosoma brucei

(2010) Teresa Cristina Leandro de Jesus et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

N-myristoyltransferase inhibitors as new leads to treat sleeping sickness

(2010) Julie A. Frearson et al.   NATURE

Expansion of the target of rapamycin (TOR) kinase family and function in Leishmania shows that TOR3 is required for acidocalcisome biogenesis and animal infectivity

(2010) L. Madeira da Silva et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

New Treatment Option for Second-Stage African Sleeping Sickness: In Vitro and In Vivo Efficacy of Aza Analogs of DB289

(2009) T. Wenzler et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

The TryPIKinome of five human pathogenic trypanosomatids: Trypanosoma brucei, Trypanosoma cruzi, Leishmania major, Leishmania braziliensis and Leishmania infantum – New tools for designing specific inhibitors

(2009) Diana Bahia et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Ku-0063794 is a specific inhibitor of the mammalian target of rapamycin (mTOR)

(2009) Juan M. García-Martínez et al.   BIOCHEMICAL JOURNAL

The discovery and optimisation of pyrido[2,3-d]pyrimidine-2,4-diamines as potent and selective inhibitors of mTOR kinase

(2009) Karine Malagu et al.   BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Antimyeloma Activity of the Orally Bioavailable Dual Phosphatidylinositol 3-Kinase/Mammalian Target of Rapamycin Inhibitor NVP-BEZ235

(2009) D. W. McMillin et al.   CANCER RESEARCH

Biochemical, Cellular, and In vivo Activity of Novel ATP-Competitive and Selective Inhibitors of the Mammalian Target of Rapamycin

(2009) K. Yu et al.   CANCER RESEARCH

mTOR and the control of whole body metabolism

(2009) Pazit Polak et al.   CURRENT OPINION IN CELL BIOLOGY

TOR signaling in invertebrates

(2009) Alexandre Soulard et al.   CURRENT OPINION IN CELL BIOLOGY

ATP-Competitive Inhibitors of the Mammalian Target of Rapamycin: Design and Synthesis of Highly Potent and Selective Pyrazolopyrimidines

(2009) Arie Zask et al.   JOURNAL OF MEDICINAL CHEMISTRY

NVP-BEZ235, a novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor, elicits multifaceted antitumor activities in human gliomas

(2009) T.-J. Liu et al.   MOLECULAR CANCER THERAPEUTICS

Take your PIK: phosphatidylinositol 3-kinase inhibitors race through the clinic and toward cancer therapy

(2009) N. T. Ihle et al.   MOLECULAR CANCER THERAPEUTICS

Regulated expression of the Leishmania major surface virulence factor lipophosphoglycan using conditionally destabilized fusion proteins

(2009) L. Madeira da Silva et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Demonstration of Genetic Exchange During Cyclical Development of Leishmania in the Sand Fly Vector

(2009) N. S. Akopyants et al.   SCIENCE

The Pharmacology of mTOR Inhibition

(2009) D. A. Guertin et al.   Science Signaling

Active-Site Inhibitors of mTOR Target Rapamycin-Resistant Outputs of mTORC1 and mTORC2

(2009) Morris E Feldman et al.   PLOS BIOLOGY

A Vascular Targeted Pan Phosphoinositide 3-Kinase Inhibitor Prodrug, SF1126, with Antitumor and Antiangiogenic Activity

(2008) J. R. Garlich et al.   CANCER RESEARCH

Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity

(2008) S.-M. Maira et al.   MOLECULAR CANCER THERAPEUTICS

Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases

(2008) Beth Apsel et al.   Nature Chemical Biology

Rapamycin inhibits trypanosome cell growth by preventing TOR complex 2 formation

(2008) A. Barquilla et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Ever-increasing complexities of diamidine and arsenical crossresistance in African trypanosomes

(2008) Harry P. de Koning   TRENDS IN PARASITOLOGY

Targeting phosphoinositide 3-kinase—Moving towards therapy

(2007) Romina Marone et al.   BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS